摘要
卵巢癌是妇科肿瘤死亡的首要原因。化疗药物在卵巢癌初始治疗时多数有效,但长时间使用则会引起肿瘤耐药性和正常组织严重损伤等,因此在复发性卵巢癌的治疗中具有局限性。分子靶向治疗作为卵巢癌治疗的新方式,近年获得了多项突破性研究成果,尤其在复发性及耐药性卵巢癌中其可以延长疾病无进展生存期,从而弥补了化疗的不足。其中,抗血管生成类药物和聚腺苷二磷酸核糖聚合酶抑制剂已逐步运用于临床治疗。此外,分子靶向治疗也可通过生物标志物进行分子分型,实现卵巢癌的个体化治疗,这将成为未来治疗研究的新趋势。本文回顾卵巢癌靶向治疗药物的研究进展,分析分子分型运用于卵巢癌治疗的前景,进而探讨分子靶向药物在卵巢癌治疗中的价值。
Ovarian cancer is still the leading cause of death from gynecological caner. Chemotherapy usually showseffectiveness in initial treatment of ovarian cancer, but resistance and toxicities increase over time which limits its use inrecurrent cases. Targeted therapy offers a new treatment of ovarian cancer and some impressive breakthroughs have beenachieved. Especially in the recurrent and resistant ovarian cancer, targeted therapy can prolong the progression free survival thatmake up for the deficiency of chemotherapy. Among them, antiangiogenic therapy and PARP inhibitors have been graduallyapplied in clinical treatment. Besides, personalized medicine could probably be realized in the future through biomarker profilesin targeted therapy. We here summarize drugs in targeted therapy of ovarian cancer, describe the prospects of biomarkers anddefine the role of molecular targeted therapy in the treatment of ovarian cancer.
出处
《国际妇产科学杂志》
CAS
2016年第4期407-411,共5页
Journal of International Obstetrics and Gynecology
基金
国家自然科学基金(81272879)
关键词
卵巢肿瘤
受体
表皮生长因子
血管生成抑制剂
聚ADP核糖聚合酶类
免疫抑制剂
治疗
Ovarian neoplasms
Receptor,epidermal growth factor
Angiogenesis inhibitors
Poly （ADP -ribose）polymerases
Immunosuppressive agents
Therapy
